Drug Approval | February 24, 2024
Orchid Pharma's 'Exblifep' receives USFDA approval
Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA
Orchid is the first company from India, ever to have invented a product which has received a New Drug Approval (NDA) from USFDA
Net product sales in the fourth quarter of 2023 include the recognition of $0.6 billion from deferred revenue, related to Gavi, the Vaccine Alliance
The launch of a DGCA Type Approved Logistics Drone facilitates critical medical deliveries to remote regions
VELSIPITY is the first and only oral advanced ulcerative colitis therapy approved for use in patients 16 years of age or older in the EU
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
Ayush is expanding beyond wellness to therapeutic wellness
_256_384.png){kind=logo}
4 FDA clearances & 61 EU MDR CE tags achieved for AI in 18 months
Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024
This is the first and only oral once-a-day therapy for testosterone suppression in patients with advanced prostate cancer in India
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Subscribe To Our Newsletter & Stay Updated
